273

---

Click the image below to view the full size version of this cover.

Issue 273: In our latest paper, we developed an agent-based model of glioblastoma treatment by immune checkpoint blockade to better understand the mechanisms of recent clinical trial failures of this immunotherapy. We integrated pharmacokinetic models of temozolomide and nivolumab to our glioblastoma growth model that accounts for the immune reaction to glioblastoma through adaptive cell signalling, including CD4+ and CD8+ T cells. Using imaging mass cytometry data of patient resections, we elucidated how factors such as localization of glioblastoma cells and CD8+ T cell infiltration impact treatment outcomes.